AFJKFinancial Services · Shell Companies

AFJK Stock Forecast: Aimei Health Technology Co., Ltd. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$12

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$38.3M
Ticker Nerd rank
67 / 100
Median analyst target
Analysts covering
Revenue$0.0
Operating income−$192K
Net income−$83K
Free cash flow−$157K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

AFJK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aimei Health Technology Co., Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Size
84
Volatility
76
Value
67
Issuance
62
Momentum
55
Quality
45
Growth
39
Revisions
25

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AFJK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AFJK, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AFJK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AFJK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Aimei Health Technology Co., Ltd. (AFJK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
172.9×

Cheaper than 4% of US stocks

Price / sales
Price / book
4.8×

Cheaper than 21% of US stocks

EV / EBITDA
−49.8×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
−75.4%

Higher than 6% of US stocks

Gross margin
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
13.2%

Higher than 71% of US stocks

Return on assets
−1.4%

Higher than 38% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aimei Health Technology Co., Ltd. (AFJK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aimei Health Technology Co., Ltd. has a market value of $38.3M and an enterprise value of $41.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: $412K.

  • Free cash flow in the twelve months to 30 June 2026: −$371K.

  • Aimei Health Technology Co., Ltd. spent $34.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 3.2M.

  • Trailing P/E: 172.9×.

  • Aimei Health Technology Co., Ltd. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

AFJK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelShell Companies
CompanyMarket capTKN rank
AFJKAimei Health Technology Co., Ltd.$38.3M
67
NOEMCO2 Energy Transition Corp.$39.3M
61
FSHPFlag Ship Acquisition Corp.$39.8M
66
LCCCLakeshore Acquisition III Corp.$40.2M
59
DTSQDT Cloud Star Acquisition Corp.$42.0M
87
IPEXInflection Point Acquisition Corp. V$43.5M
50
QETAQuetta Acquisition Corp.$44.4M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aimei Health Technology Co., Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Frequently asked questions about AFJK stock

How does Ticker Nerd's model rank AFJK?

As at 19 Sept 2026, Aimei Health Technology Co., Ltd. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

What is the AFJK stock forecast for 2030?

No analyst covering Aimei Health Technology Co., Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFJK are extrapolating price history, which says nothing about the business.

What does Aimei Health Technology Co., Ltd. do?

Aimei Health Technology Co., Ltd. Ordinary Share is the common equity of Aimei Health Technology Co., Ltd., a blank check company organized to pursue a business combination with one or more operating businesses.

Company

About Aimei Health Technology Co., Ltd.

Aimei Health Technology Co., Ltd. Ordinary Share is the common equity of Aimei Health Technology Co., Ltd., a blank check company organized to pursue a business combination with one or more operating businesses. The ordinary shares represent an ownership interest in the company and are used in the public markets as the core security tied to its capital structure. Aimei Health Technology Co., Ltd. focuses on merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar transactions, making its shares relevant to investors tracking special purpose acquisition companies. The company is headquartered in New York and operates with a streamlined corporate structure typical of SPAC issuers, with limited operating activities before completing a transaction. Its ordinary shares trade separately from the company’s rights and unit securities, reflecting their role as a standalone market instrument.

CEO Mr. Junheng Xie · United States